



RECEIVED

JUN 11 2001

Docket No.: 19603/4071

PATENT  
TECH CENTER 1600/2900  
1558A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Vivian E. Mack Strong, et al.

Serial No. : 09/782,936

Cnfrm. No. : 1665

Filed : February 14, 2001

For : USE OF COX-2 INHIBITORS TO TREAT  
SEPSIS AND COMPLICATIONS THEREOF,  
AND EP RECEPTOR MODULATION

Examiner:  
Unknown

Art Unit:  
1614

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

1. Andrews N.C. and Faller D.V., A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. *Nucleic Acids Research* 19(9):2499, 1991.
2. Baker, C.C., Oppenheimer, L., Stephens, B., Lewis, F.R., and Trundey, D.D. Epidemiology of trauma deaths. *Am. J. Surg.* 140: 144, 1980.
3. Boyum, A., Isolation of mononuclear cells and granulocytes from human blood. *Clin. Lab. Inves. Supp.* 21:77-79, 1968.
4. Ertel, W., Singh, G., Morrison, M.G., Ayala, A., and Chaudry, I.H. Chemically induced hypotension increases PGE<sub>2</sub> release and depresses macrophage antigen presentation. *Am. J. Physiol.* 264: R655, 1993.

5. Faist, E., Mew, A., Baker, C.C., Strasser, T., Alkan, S.S., and Rieber, P., Heberer, G. Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)-dependent suppression of interleukin-2 production in patients with major trauma. *J. Trauma*. 27: 837, 1987.
6. Fletcher, J.R., and Ramwell, P.W. Indomethacin improves survival after endotoxin in baboons. *Adv. Prostaglandin. Thromboxane Res.* 7: 821, 1980.
7. Fukushima, R., Alexander, J.W., Wu, J.Z., and Mao, J.X., Szczur, K., Stephens, A.M., Ogle, J.D., Ogle C.K. Time course of production of cytokines and prostaglandin E<sub>2</sub> by macrophages isolated after thermal injury and bacterial translocation. *Circ. Shock*. 42: 154, 1994.
8. Futaki, N., Takanashi, S., Yokohama, M., Arai, I., Higuchi, S., and Otomo, S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity *in vitro*. *Prostaglandins*. 47: 55, 1994.
9. Gabay, D., and Kushner, I. Acute-phase proteins and other systemic responses to inflammation. *N. Engl. J. Med.* 340: 448, 1999.
10. Grbic, J.T., Mannick, J.A., Gough, D.B., and Rodrick, M.L. The role of prostaglandin E<sub>2</sub> in immune suppression following injury. *Ann. Surg.* 214: 253, 1987.
11. Hinshaw, L.B., Solomon, L.A., Erdos, E.F., Reins, D.A., and Gunter, B.J. Effects of acetylsalicylic acid on the canine response to endotoxin. *J. Pharmacol. Exp. Ther.* 157: 665, 1967.
12. Hinson, R.M., Williams, J.A., and Shacter, E. Elevated interleukin 6 is induced by prostaglandin E<sub>2</sub> in a murine model of inflammation: possible role of cyclooxygenase-2. *Proc. Natl. Acad. Sci. U.S.A.* 93: 485, 1996.
13. Lin, E., Calvano, S.E., and Lowry, S.F. Inflammatory cytokines and cell response in surgery. *Surgery*. 127: 117, 2000.
14. Mack, V., McArter, M.D., Naama, H.A., Calvano, S.E., Daly, J.M., Dominance of T-Helper 2-type cytokines after severe injury. *Arch. Surg.* 31:1303-1309, December, 1996.
15. Mack Strong et al., "Blocking Prostaglandin E<sub>2</sub> After Trauma Attenuates Pro-Inflammatory Cytokines and Improves Survival," *Shock*, Vol. 14, No. 3: 374-379 (2000).

16. Mack, V.E., et al. "Blocking Prostaglandin-E2 after Trauma is Associated with decrease Cox-2 mRNA Expression and Survival," abstract published April 20, 2000, Annual Meeting of the Surgical Infection Society.
17. Mack, V.E., et al. "Trauma Induces Prostaglandins and Cox-2 mRNA in Human and Experimental Models. Could Cox-2 Inhibitors be the Cure?" abstract, published April 20, 2000, Annual Meeting of the Surgical Infection Society.
18. McCarter, M.D., Mack, V.E., Daly, J.M., Naama, H.A., Calvano, S.E. Trauma-induced alterations in macrophage function. *Surgery*. 123: 96, 1998.
19. O'Sullivan, S.T., Lederer, J.A., Horgan, A.F., Chin, D.H.L., Mannick, J.A., and Rodrick, M.L. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. *Ann. Surg.* 222: 482, 1995.
20. Parratt, J.R., and Sturgess, R.M. *E. coli* endotoxin shock in the cat: treatment with indomethacin. *Br. J. Pharmacol.* 53: 485, 1975.
21. Rangel-Fausto MS et al., (1995) "The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. *JAMA* 273:117-23.
22. Rangel-Fausto MS et al., "Increases in National Hospital Discharge Survey Rates for Septicemia- United States, 1979-1987: *Morb. Mortal. Wkly Rep.* 39:31-4, 1990."
23. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature (London)*. 231: 232, 1971.
24. Versteeg, J.J., van Vergen en Henefouwen, P.M.P., van Deventer, S.J.H., and Peppelenbosch, M.P. Cyclooxygenase-dependent signaling: molecular events and consequences. *FEBS Lett.* 445:1, 1999.
25. Zellweger, R., Ayala, A., Zhu, X.L., Morrison, M.H., and Chaudry, I.H. Effect of surgical trauma on splenocyte and peritoneal macrophage immune function. *J. Trauma*. 39: 645, 1995.
26. U.S. Patent No. 5,633,272 to Talley et al., issued May 27, 1997
27. U.S. Patent No. 5,731,343 to Feng et al., issued March 24, 1998.
28. U.S. Patent No. 5,905,089 to Hwang et al., issued May 18, 1999.
29. U.S. Patent No. 6,048,850 to Young et al., issued April 11, 2000.
30. International Patent Application WO 99/30721 A1, published June 24, 1999.


Copies of each of the references are also provided herewith. All of the references are in the English language.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present invention as defined in 37 C.F.R. § 1.56(a).

Inasmuch as this Information Disclosure Statement is being submitted prior to the issuance of an Official Action on the merits, no fee, certification or petition is required by Applicants.

Respectfully submitted,

Date: June 5, 2001


  
Ann R. Pokalsky  
Registration No. 34,697

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (716) 263-1304  
Facsimile: (716) 263-1600

ARP/mm

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)**

I certify that the attached correspondence is being deposited on 6/5/01 with the U.S. Postal Service as first class mail under 37 C.F.R. § 1.8 and addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Maria I. Matos